Log in

Relevant bibliographies by topics / Cancer – Surveillance active / Journal articles

To see the other types of publications on this topic, follow the link: Cancer – Surveillance active.

Journal articles on the topic 'Cancer – Surveillance active'

Author: Grafiati

Published: 4 June 2021

Last updated: 7 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Cancer – Surveillance active.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Dall’Era, Marc A., Benjamin J. Davies, and Scott Eggener. "Active surveillance for prostate cancer." Translational Andrology and Urology 7, no. 2 (April 2018): 195–96. http://dx.doi.org/10.21037/tau.2018.03.03.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Shill, Daniela K., Monique J. Roobol, Behfar Ehdaie, Andrew J. Vickers, and Sigrid V. Carlsson. "Active surveillance for prostate cancer." Translational Andrology and Urology 10, no. 6 (June 2021): 2809–19. http://dx.doi.org/10.21037/tau-20-1370.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

İzol, Volkan, and Nebil Akdoğan. "Active Surveillance in Prostate Cancer." Üroonkoloji Bülteni 16, no. 4 (December 20, 2017): 127–32. http://dx.doi.org/10.4274/uob.820.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Tay, Kae Jack, Melissa Mendez, Judd W. Moul, and Thomas J. Polascik. "Active surveillance for prostate cancer." Current Opinion in Urology 25, no. 3 (May 2015): 185–90. http://dx.doi.org/10.1097/mou.0000000000000168.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Singer, Eric A., Aradhana Kaushal, Baris Turkbey, Anna Couvillon, Peter A. Pinto, and Howard L. Parnes. "Active surveillance for prostate cancer." Current Opinion in Oncology 24, no. 3 (May 2012): 243–50. http://dx.doi.org/10.1097/cco.0b013e3283527f99.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Lees, Kathryn, Meeta Durve, and Chris Parker. "Active surveillance in prostate cancer." Current Opinion in Urology 22, no. 3 (May 2012): 210–15. http://dx.doi.org/10.1097/mou.0b013e328351dc47.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Romero-Otero, Javier, Borja García-Gómez, José M. Duarte-Ojeda, Alfredo Rodríguez-Antolín, Antoni Vilaseca, Sigrid V. Carlsson, and Karim A. Touijer. "Active surveillance for prostate cancer." International Journal of Urology 23, no. 3 (November 30, 2015): 211–18. http://dx.doi.org/10.1111/iju.13016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Thompson, Ian M., and Laurence Klotz. "Active Surveillance for Prostate Cancer." JAMA 304, no. 21 (December 1, 2010): 2411. http://dx.doi.org/10.1001/jama.2010.1761.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Saad, Fred. "Active Surveillance in Prostate Cancer." JAMA Oncology 1, no. 3 (June 1, 2015): 340. http://dx.doi.org/10.1001/jamaoncol.2015.103.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Matulewicz, Richard S., Adam B. Weiner, and Edward M. Schaeffer. "Active Surveillance for Prostate Cancer." JAMA 318, no. 21 (December 5, 2017): 2152. http://dx.doi.org/10.1001/jama.2017.17222.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Schröder, Fritz H. "Active Surveillance for Localized Prostate Cancer." Lancet Oncology 13, no. 12 (December 2012): 1200. http://dx.doi.org/10.1016/s1470-2045(12)70543-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Van Veldhuizen, Peter J. "Prostate Cancer Active Surveillance: Quality Matters." Journal of the National Comprehensive Cancer Network 21, no. 5 (May 2023): 529–30. http://dx.doi.org/10.6004/jnccn.2023.7030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Hashine, Katsuyoshi, Hiroyuki Iio, Yoshiteru Ueno, Shohei Tsukimori, and Iku Ninomiya. "Surveillance biopsy and active treatment during active surveillance for low-risk prostate cancer." International Journal of Clinical Oncology 19, no. 3 (June 22, 2013): 531–35. http://dx.doi.org/10.1007/s10147-013-0584-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Tohi, Yoichiro, Takuma Kato, and Mikio Sugimoto. "Aggressive Prostate Cancer in Patients Treated with Active Surveillance." Cancers 15, no. 17 (August 25, 2023): 4270. http://dx.doi.org/10.3390/cancers15174270.

Full text

Abstract:

Active surveillance has emerged as a promising approach for managing low-risk and favorable intermediate-risk prostate cancer (PC), with the aim of minimizing overtreatment and maintaining the quality of life. However, concerns remain about identifying “aggressive prostate cancer” within the active surveillance cohort, which refers to cancers with a higher potential for progression. Previous studies are predictors of aggressive PC during active surveillance. To address this, a personalized risk-based follow-up approach that integrates clinical data, biomarkers, and genetic factors using risk calculators was proposed. This approach enables an efficient risk assessment and the early detection of disease progression, minimizes unnecessary interventions, and improves patient management and outcomes. As active surveillance indications expand, the importance of identifying aggressive PC through a personalized risk-based follow-up is expected to increase.

APA, Harvard, Vancouver, ISO, and other styles

15

Ehdaie, Behfar. "Active surveillance for prostate cancer: is it too active?" BJU International 118, no. 3 (August 14, 2016): 343. http://dx.doi.org/10.1111/bju.13473.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Albertsen, Peter. "Should patients consider active surveillance?" Cancer 112, no. 12 (June 15, 2008): 2631–34. http://dx.doi.org/10.1002/cncr.23500.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Ansari, Jawaher, Lillian White, Hilary Glen, Brian McGlynn, Robert Nairn, Margaret Balsitis, Graham Hollins, et al. "Active surveillance for prostate cancer: Scottish experience." Journal of Clinical Oncology 30, no. 5_suppl (February 10, 2012): 167. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.167.

Full text

Abstract:

167 Background: Prostate cancer is the second most common malignancy in men worldwide with 910,000 cases registered in 2008. The prognosis for low-risk prostate cancer patients remains excellent and arguably the majority may either not require radical treatment or may benefit from deferred radical treatment. Active surveillance involves serial prostate-specific antigen (PSA) monitoring, digital rectal examinations, and periodic trans-rectal ultrasound guided prostate biopsies. Patients for active surveillance are carefully selected, counselled and actively followed-up. Radical treatment is deferred until there is evidence of biochemical, pathological or clinical disease progression. Methods: Retrospective review of prostate cancer patients enrolled on to the active surveillance program within NHS Ayrshire and Arran Hospitals. Clinical examination and PSA monitoring was undertaken 3-monthly in year 1, 4-monthly in year 2 and 6-monthly thereafter. The protocol stipulates repeat TRUS biopsies at years 1, 4, 7 and every 3 years thereafter. Results: 105 patients with low-intermediate risk prostate cancer with a median age of 68yrs (48–78yrs) were followed for a median duration of 30 months (4–152 months). The median PSA at presentation was 7ng/ml (0.5-31). Repeat biopsies were performed in 82 patients and 37% had no histological evidence of cancer. The median time to re-biopsy was 16 months (10–85 months). Of the patients who received radical treatment; 3 underwent radical prostatectomy and 23 received radical radiotherapy. The indications for radical treatment were pathological progression in 73%, PSA progression in 23% and co-existing bladder cancer in 4%. One patient died due to unrelated medical problems and one patient developed metastatic disease. Conclusions: With appropriate counselling, a significant percentage of men with low-moderate risk prostate cancer choose active surveillance. In this study, active surveillance does not appear to compromise outcomes for patients with low-intermediate risk prostate cancer. Less then 25% of patients needed radical treatment and therefore this approach appears cost-effective and avoids treatment-related morbidity.

APA, Harvard, Vancouver, ISO, and other styles

18

Lantz, Anna, Henrik Olsson, Tobias Nordström, Fredrik Jäderling, Lars Egevad, Magnus Annerstedt, Henrik Gronberg, and Martin Eklund. "Incorporating mpMRI and biomarkers in active surveillance protocols: The prospective Stockholm3 Active Surveillance trial (STHLM3AS)." Journal of Clinical Oncology 38, no. 6_suppl (February 20, 2020): TPS379. http://dx.doi.org/10.1200/jco.2020.38.6_suppl.tps379.

Full text

Abstract:

TPS379 Background: Level one evidence shows that men with low-risk prostate cancer undergoing active surveillance (AS) with repeated PSA tests and systematic biopsies have low mortality. However, monitoring sometimes misses significant cancer progression and causes patient morbidity. The objective of this study is to evaluate a new proposed protocol for AS using the combination of the Stockholm3 test and MRI targeted biopsies in comparison to conventional follow-up using PSA and systematic biopsies. Methods: A prospective multicenter study with paired design was used to evaluate our proposed protocol (Stockholm3, MRI, targeted biopsies) compared with the conventional protocol according to Swedish National Guidelines (PSA, systematic biopsies) for follow-up of men on AS. The STHLM3 study was performed between 2012-2014. In the study 1 374 men were diagnosed with ISUP grade 1 disease. Out of these, 541 men currently on AS were invited to the STHLM3AS study. Eligible individuals had to be alive without any severe comorbidity, without contraindications for MRI and without a history of initiating prostate cancer treatment. The primary endpoint ISUP grade ≥2 cancer and the secondary endpoint number of performed biopsies will be evaluated using relative sensitivity (RS). At baseline a blood test for PSA and Stockholm3 test as well as a bi-parametric MRI was performed. For men with PIRADS ≥ 3 targeted and systematic biopsies were performed. For men with PIRADS < 3 only systematic biopsies were performed. The study is registered at ClinicalTrials.gov (NCTNCT03956108). Results: 301 men on AS have been included in the study. Since this is a trial in progress, no results will be presented. Conclusions: To our knowledge, this is the largest prospective multicenter study evaluating the performance of MRI for disease monitoring in an AS-cohort. Prediction models using biomarkers and MRI will likely both have an increasing role in the monitoring of AS patients in the future. We hypothesise that the sequential use of first Stockholm3 test followed by MRI will decrease the number of biopsies, while retaining the sensitivity to detect ISUP grade ≥2 cancer compared with using systematic biopsies in all men. Clinical trial information: NCTNCT03956108.

APA, Harvard, Vancouver, ISO, and other styles

19

Aragon-Ching, Jeanny B., Heather M. Hussey, Hong Nguyen, Dechang Chen, Donald Henson, and Samuel J. Simmens. "Treatment utilization patterns for prostate cancer (PCa): An analysis from the National Cancer Database (NCDB)." Journal of Clinical Oncology 35, no. 6_suppl (February 20, 2017): 99. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.99.

Full text

Abstract:

99 Background: We previously reported the effects of the PSA screening guidelines on the patterns of diagnosis and treatment for PCa based on analyses from the NCDB dataset (Aragon-Ching et al., ASCO GU 2016). Given increasing use and advocacy for active surveillance, we now report on the treatment utilization patterns for PCa by facility type and overall incidence of active treatment (surgery or radiation), no treatment, or active surveillance by PCa stage using the NCDB dataset. Methods: Using a de-identified dataset acquired from NCDB from 1998 to 2012, treatment status of all 337,568 men for which information was available was tabulated according to whether active treatment, no treatment, or active surveillance (i.e. watchful waiting) was performed. Patient characteristics, stage, and treatment status by facility type was determined. Results: There were 1,802,596 patients diagnosed with prostate cancer between 1998 and 2012 in the NCDB. Of the 337,568 men for which treatment status was available, 92% received treatment, nearly 4% were under active surveillance, and another 4% did not receive any form of treatment or active surveillance. Of patients diagnosed with TNM Stage I and II PCa, only 7.5% and 2.22%, respectively, were followed under active surveillance. Overall, active surveillance was most utilized (n = 7,524; 5.7% of men) in academic research programs compared to other treatment facilities. Of the 310,898 men who received any form of active treatment, 193,889 men (62.3%) received surgery and 108,925 men (35%) received radiation. Conclusions: Active surveillance as a treatment modality comprised only a minority of patients who underwent treatment for PCa from 1998–2012, even among men with early Stage I and II Pca. Interestingly, the majority of the men who did receive active surveillance as their treatment option were treated at academic research programs, perhaps alluding to increased recognition and adherence to the PSA screening and active surveillance guidelines compared to other treatment facility types. Datasets including PCa patients beyond 2012 will be explored to further evaluate these changes in treatment modalities.

APA, Harvard, Vancouver, ISO, and other styles

20

Klotz, Laurence. "Active Surveillance for Prostate Cancer: For Whom?" Journal of Clinical Oncology 23, no. 32 (November 10, 2005): 8165–69. http://dx.doi.org/10.1200/jco.2005.03.3134.

Full text

Abstract:

Prostate-specific antigen (PSA) –based prostate cancer screening results in the diagnosis of prostate cancer in many men who are not destined to have clinical progression during their lifetime. Good-risk prostate cancer, defined as a Gleason score of 6 or less, PSA < 10, and T1c to T2a, now constitutes 50% of newly diagnosed prostate cancer. In most of these patients, the disease is indolent and slow growing. The challenge is to identify those patients who are unlikely to experience significant progression while offering radical therapy to those who are at risk. The approach to favorable-risk prostate cancer described in this article uses estimation of PSA doubling time (PSA DT) to stratify patients according to the risk of progression. Patients who select this approach are managed initially with active surveillance. Those who have a PSA DT of 3 years or less (based on a minimum of three determinations over 6 months) are offered radical intervention. The remainder are closely monitored with serial PSA and periodic prostate rebiopsies (at 2, 5, and 10 years). In this series of 299 patients, the median DT was 7 years. Forty-two percent had a PSA DT > 10 years, and 20% had a PSA DT > 100 years. The majority of patients on this study remain under surveillance. The approach of active surveillance with selective delayed intervention based on PSA DT represents a practical compromise between radical therapy for all (which results in overtreatment for patients with indolent disease) and watchful waiting with palliative therapy only (which results in undertreatment for those with aggressive disease).

APA, Harvard, Vancouver, ISO, and other styles

21

Nayan, Madhur, Filipe L. F. Carvalho, and Adam S. Feldman. "Active surveillance for intermediate-risk prostate cancer." World Journal of Urology 40, no. 1 (January 2022): 79–86. http://dx.doi.org/10.1007/s00345-021-03893-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Wysong, Pippa. "Prostate Cancer Patients Benefit From Active Surveillance." Oncology Times 43, no. 19 (October 5, 2021): 22. http://dx.doi.org/10.1097/01.cot.0000795988.89134.8a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Porreca, Angelo, Michele Colicchia, Gian Maria Busetto, and Matteo Ferro. "MRI and Active Surveillance for Prostate Cancer." Diagnostics 10, no. 8 (August 14, 2020): 590. http://dx.doi.org/10.3390/diagnostics10080590.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Carter, H. Ballentine. "Active surveillance for favorable risk prostate cancer." Current Opinion in Urology 25, no. 3 (May 2015): 230–31. http://dx.doi.org/10.1097/mou.0000000000000167.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Elnahla, Ahmed, Abdallah S. Attia, Emmanuelle Ruiz, Scott Mayer, Grace Lee, and Emad Kandil. "Active surveillance for well-differentiated thyroid cancer." Annals of Thyroid 5 (December 2020): 22. http://dx.doi.org/10.21037/aot-20-25.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Hadjipavlou, Marios, John Promponas, and Sanjeev Madaan. "Active surveillance for low-risk prostate cancer." Journal of Clinical Urology 8, no. 6 (July 7, 2015): 420–28. http://dx.doi.org/10.1177/2051415815592816.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Klotz, Laurence. "Active surveillance in intermediate-risk prostate cancer." BJU International 125, no. 3 (January 16, 2020): 346–54. http://dx.doi.org/10.1111/bju.14935.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Dariane, C. "Surveillance active du cancer de la prostate." Progrès en Urologie 25, no. 14 (November 2015): 884–87. http://dx.doi.org/10.1016/j.purol.2015.06.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Willder, J., T. Qayyum, R. Clark, J. Edwards, and M. Underwood. "UP-02.179 Active Surveillance for Prostate Cancer." Urology 78, no. 3 (September 2011): S322—S323. http://dx.doi.org/10.1016/j.urology.2011.07.997.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

The Lancet. "Active surveillance for early-stage prostate cancer." Lancet 383, no. 9913 (January 2014): 188. http://dx.doi.org/10.1016/s0140-6736(14)60058-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Klotz, Laurence. "Active Surveillance for Favorable Risk Prostate Cancer." Journal of Urology 182, no. 6 (December 2009): 2565–66. http://dx.doi.org/10.1016/j.juro.2009.09.038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Klotz, Laurence. "Active surveillance for genitourinary cancer: An overview." Urologic Oncology: Seminars and Original Investigations 24, no. 1 (January 2006): 44–45. http://dx.doi.org/10.1016/j.urolonc.2005.07.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Tiu, Albert, Lawrence C. Jenkins, and Mark S. Soloway. "Active surveillance for low-risk bladder cancer." Urologic Oncology: Seminars and Original Investigations 32, no. 1 (January 2014): 33.e7–33.e10. http://dx.doi.org/10.1016/j.urolonc.2012.12.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Raghavan, D. "‘Active surveillance’ for stage I testis cancer." European Journal of Cancer 36, no. 15 (October 2000): 1891–94. http://dx.doi.org/10.1016/s0959-8049(00)00163-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Ediz, C., Ö. Yilmaz, F. Ates, S. Akan, U. Sariogullari, S. Cakmak, M. C. Temel, and H. Hayit. "Low risk prostate cancer - active surveillance outcomes." European Urology Supplements 17, no. 5 (July 2018): e2194. http://dx.doi.org/10.1016/s1569-9056(18)32607-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Drouin, S. J., M. Rouprêt, F. Hamdy, and N. Mottet. "Surveillance active du cancer de prostate localisé." Progrès en Urologie 20 (June 2010): S181—S185. http://dx.doi.org/10.1016/s1166-7087(10)70036-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Bangma, Chris H., Meelan Bul, Theo H. van der Kwast, Tom Pickles, Ida J. Korfage, Caroline M. Hoeks, Ewout W. Steyerberg, et al. "Active surveillance for low-risk prostate cancer." Critical Reviews in Oncology/Hematology 85, no. 3 (March 2013): 295–302. http://dx.doi.org/10.1016/j.critrevonc.2012.07.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Klotz, Laurence. "Active surveillance for low-risk prostate cancer." Current Opinion in Urology 27, no. 3 (May 2017): 225–30. http://dx.doi.org/10.1097/mou.0000000000000393.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Herrera-Caceres, Jaime O., and Michael A. S. Jewett. "Roles for active surveillance in renal cancer." Current Opinion in Urology 28, no. 4 (July 2018): 375–82. http://dx.doi.org/10.1097/mou.0000000000000506.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Overland, Maya R., Samuel L. Washington, Peter R. Carroll, Matthew R. Cooperberg, and Annika Herlemann. "Active surveillance for intermediate-risk prostate cancer." Current Opinion in Urology 29, no. 6 (November 2019): 605–11. http://dx.doi.org/10.1097/mou.0000000000000671.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Payne, Ryan, Nataniel Lester-Coll, and Christopher Anker. "Active Surveillance for Early Stage Lung Cancer." International Journal of Radiation Oncology*Biology*Physics 108, no. 2 (October 2020): E50. http://dx.doi.org/10.1016/j.ijrobp.2020.02.587.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Miyake, Makito, Kiyohide Fujimoto, and Yoshihiko Hirao. "Active surveillance for nonmuscle invasive bladder cancer." Investigative and Clinical Urology 57, Suppl 1 (2016): S4. http://dx.doi.org/10.4111/icu.2016.57.s1.s4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Dall'Era, M. A., and L. Klotz. "Active surveillance for intermediate-risk prostate cancer." Prostate Cancer and Prostatic Diseases 20, no. 1 (November 1, 2016): 1–6. http://dx.doi.org/10.1038/pcan.2016.51.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Klotz, Laurence. "Active Surveillance for Prostate Cancer: A Review." Current Urology Reports 11, no. 3 (April 20, 2010): 165–71. http://dx.doi.org/10.1007/s11934-010-0110-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Ploussard, G., C. Hennequin, and F. Rozet. "Surveillance active du cancer de la prostate." Cancer/Radiothérapie 21, no. 6-7 (October 2017): 437–41. http://dx.doi.org/10.1016/j.canrad.2017.07.027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

O'Donnell, Helen, and Chris Parker. "Treatment of early prostate cancer: active surveillance." Trends in Urology, Gynaecology & Sexual Health 14, no. 3 (May 2009): 15–19. http://dx.doi.org/10.1002/tre.109.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Merriel, Sam. "Active surveillance for prostate cancer: an update." Trends in Urology & Men's Health 11, no. 1 (January 2020): 8–11. http://dx.doi.org/10.1002/tre.727.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Zanocco, Kyle A., Jerome M. Hershman, and Angela M. Leung. "Active Surveillance of Low-Risk Thyroid Cancer." JAMA 321, no. 20 (May 28, 2019): 2020. http://dx.doi.org/10.1001/jama.2019.5350.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Dall'Era, Marc A., Matthew R. Cooperberg, June M. Chan, Benjamin J. Davies, Peter C. Albertsen, Laurence H. Klotz, Christopher A. Warlick, et al. "Active surveillance for early-stage prostate cancer." Cancer 112, no. 8 (2008): 1650–59. http://dx.doi.org/10.1002/cncr.23373.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Albers, Patrick, Betty Wang, Stacey Broomfield, Wendy Tu, Christopher Fung, Adam Kinnaird, and Anaïs Medina Martín. "MICROULTRASOUND IN CANCER – ACTIVE SURVEILLANCE (MUSIC-AS)." Urologic Oncology: Seminars and Original Investigations 42 (March 2024): S82—S83. http://dx.doi.org/10.1016/j.urolonc.2024.01.232.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!